Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Capivasertib When Administered Alone and In Combination With Itraconazole

NCT04712396 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04712396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04712396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Capivasertib When Administered Alone and In Combination With Itraconazole
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
February 1, 2021
Completion date
March 25, 2021
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers (intended indication: metastatic patients with triple negative or hr+ breast cancer, or hormone sensitive prostate cancer)